Valneva Se · EURONEXT:VLA
Valneva — Goldman Sachs Biotech Symposium (September 2021)
21 slides from Valneva's conference presentation, September 2021
Slide 1: Advancing Vaccines for Better Lives
Advancing Vaccines for Better Lives Company Presentation Goldman Sachs Biotech Symposium
Slide 2: Disclaimer
Disclaimer This presentation does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, Valneva SE shares to any person in the USA or in any jurisdiction to whom or in which such offer or solicitation is unlawful. Valneva is a European company. Information d
Slide 3: Valneva in Summary
Valneva in Summary We are a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need Highly specialized and targeted approach to development of unique prophylactic vaccines Advanced pipeline of
Slide 4: Research & Development
Research & Development
Slide 5: Valneva Has An Advanced Clinical Pipeline
Valneva Has An Advanced Clinical Pipeline Upcoming Development Program Discovery Pre-Clinical Phase 1 Phase 2 Phase 3 Commercial Milestones Partners VLA151: Further Ph 2 Lyme disease data late 2021 Clinical Portfolio Potentially VLA15532: Final Clinical eligible for PRV Chikungunya Data VLA2001: Ph
Slide 6: Lyme Disease Vaccine – VLA15
Lyme Disease Vaccine – VLA15
Slide 7: Lyme Disease Is a Major Health Issue
Lyme Disease Is a Major Health Issue Severe Tick-transmitted Infection, Increasingly Common in the US and Europe Early signs include flu-like symptoms1 and Erythema migrans rash2 which, if left untreated, can spread to joints (arthritis), heart (carditis) and cause neurological problems Spread of Ly
Slide 8: VLA15 – Multivalent Lyme Disease Vaccine Candidate
VLA15 – Multivalent Lyme Disease Vaccine Candidate Only Lyme Disease Program in Advanced Clinical Development Today 1 FDA Fast Track Designation granted Initial results reported from Phase 2 trials 1, 2, Recruitment completed for 2 Phase 2 trial VLA15-221 incl. pediatric participants3 Multivalent va
Slide 9: SARS-CoV-2 (COVID-19) Vaccine – VLA2001
SARS-CoV-2 (COVID-19) Vaccine – VLA2001
Slide 10: Valneva's Response to the Global COVID-19 Crisis
Valneva’s Response to the Global COVID-19 Crisis Well-Known Inactivated Approach Based on Proven Technology Intended for active immunization of at-risk populations to prevent carriage and symptomatic infection with COVID-19 during the ongoing pandemic and potentially later for routine vaccination, i
Slide 11: VLA2001 – The Only Inactivated Vaccine in Clinical Development in Europe
VLA2001 – The Only Inactivated Vaccine in Clinical Development in Europe UK government deal worth up to €1.4 billion1 with development and manufacturing funding; 1 ongoing dialogue with the European Commission acceleration enabled through use of Valneva’s FDA-registered facility in 2 Program UK; com
Slide 12: VLA2001: Development Outlook
VLA2001: Development Outlook Phase 3 trial “Cov-Compare” Recruitment Completed1; Rolling Submission to MHRA has Commenced2 “Cov-Compare” (VLA2001-301) is a randomized, observer-blind, controlled, comparative immunogenicity trial in over 4,000 adults Immunological comparison against a licensed vacc
Slide 13: Chikungunya Vaccine – VLA1553
Chikungunya Vaccine – VLA1553
Slide 14: VLA1553: Only Chikungunya Vaccine Candidate in Phase 3 Today
VLA1553: Only Chikungunya Vaccine Candidate in Phase 3 Today Positive Topline Results for Phase 3 trial VLA1553-301 reported1; Use of surrogate marker for 1 Phase 3 endpoint confirmed by FDA2; Accelerated Approval Pathway confirmed3 Potentially eligible for Priority Review Voucher4; FDA Fast Track5
Slide 15: VLA1553: Development Outlook
VLA1553: Development Outlook Pivotal Phase 3 Trial – Final Data Expected Within the Next 6 Months Most advanced clinical development program in the world Pivotal Phase 3 safety and immunogenicity trial progressing towards final analysis, expected within the next six months1 Lot-to-Lot consistenc
Slide 16: Commercial Products
Commercial Products
Slide 17: Specialist Travel Vaccine Business and Contractor to the US Military
Valneva Has a Specialist Travel Vaccine Business and is a Contractor to the US Military Prior to the pandemic, Valneva demonstrated a strong track record of sales growth built upon the solid foundation of its business relationship with the US DoD — €129.5m of product sales in 2019 (+25% AER, +22%
Slide 18: Corporate Highlights and Newsflow
Corporate Highlights and Newsflow
Slide 19: Strong Cash Position of €329.8 million at End of June
Strong Cash Position of €329.8 million at End of June including Proceeds from US IPO Cash / cash equivalents of €329.8 million at end of June (including proceeds from Global Offering) The increase in liquid funds compared to December 31, 2020 results from payments made by the UK government withi
Slide 20: Key Upcoming Catalysts and Potential Inflection Points
Key Upcoming Catalysts and Potential Inflection Points Chikungunya vaccine candidate VLA1553 Final Phase 3 trial results Topline data of clinical lot-to-lot consistency Phase 3 trial Lyme disease vaccine candidate VLA15 Further Phase 2 milestones and read-outs COVID-19 vaccine candidate VLA200
Slide 21: Thank you
Thank you Merci Danke Tack WaAvalneva
Valneva — Goldman Sachs Biotech Symposium (September 2021) on 6ix